Cue Biopharma Inc (CUE)

$2.82

+0.21

(+8.05%)▲

Market is closed - opens 8 PM, 06 Dec 2023

Insights on Cue Biopharma Inc

  • Increasing Revenue

    Revenue is up for the last 6 quarters, 26.0K → 2.1M (in $), with an average increase of 51.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -14.45M → -11.00M (in $), with an average increase of 9.8% per quarter

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 83.0% return, outperforming this stock by 97.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 20.4% return, outperforming this stock by 99.5%

Performance

  • $2.57
    $2.92
    $2.82
    downward going graph

    8.87%

    Downside

    Day's Volatility :11.99%

    Upside

    3.42%

    downward going graph
  • $1.70
    $5.12
    $2.82
    downward going graph

    39.72%

    Downside

    52 Weeks Volatility :66.8%

    Upside

    44.92%

    downward going graph

Returns

PeriodCue Biopharma IncSector (Health Care)Index (Russel 2000)
3 Months
5.22%
0.3%
0.0%
6 Months
-25.4%
1.7%
0.0%
1 Year
-14.02%
-4.0%
-2.4%
3 Years
-79.26%
17.2%
-6.5%

Highlights

Market Capitalization
108.5M
Book Value
$0.95
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.2
Wall Street Target Price
10.25
Profit Margin
0.0%
Operating Margin TTM
-543.76%
Return On Assets TTM
-45.8%
Return On Equity TTM
-111.08%
Revenue TTM
3.8M
Revenue Per Share TTM
0.09
Quarterly Revenue Growth YOY
2988.2000000000003%
Gross Profit TTM
1.2M
EBITDA
-52.6M
Diluted Eps TTM
-1.2
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.13
EPS Estimate Next Year
-1.11
EPS Estimate Current Quarter
-0.34
EPS Estimate Next Quarter
-0.35

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Cue Biopharma Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 263.48%

Current $2.82
Target $10.25

Technicals Summary

Sell

Neutral

Buy

Cue Biopharma Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cue Biopharma Inc
Cue Biopharma Inc
10.59%
-25.4%
-14.02%
-79.26%
-40.13%
Moderna, Inc.
Moderna, Inc.
8.62%
-38.31%
-54.89%
-50.93%
320.86%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.38%
9.73%
9.82%
65.7%
115.07%
Novo Nordisk A/s
Novo Nordisk A/s
-1.43%
23.95%
58.41%
192.13%
336.59%
Seagen, Inc.
Seagen, Inc.
0.74%
10.42%
83.05%
20.41%
247.89%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-8.19%
7.19%
13.58%
55.97%
97.18%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cue Biopharma Inc
Cue Biopharma Inc
NA
NA
NA
-1.13
-1.11
-0.46
0.0
0.95
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.72
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
23.18
23.18
1.75
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
41.18
41.18
4.02
2.67
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.38
26.38
0.5
15.04
0.23
0.14
0.0
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cue Biopharma Inc
Cue Biopharma Inc
Buy
$108.5M
-40.13%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$30.4B
320.86%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$88.5B
115.07%
23.18
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$459.0B
336.59%
41.18
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.2B
247.89%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.5B
97.18%
26.38
35.94%

Institutional Holdings

  • Slate Path Capital LP

    5.32%

  • BlackRock Inc

    4.72%

  • Vanguard Group Inc

    4.71%

  • Geode Capital Management, LLC

    1.69%

  • Bleichroeder LP

    1.67%

  • State Street Corporation

    1.55%

Corporate Announcements

  • Cue Biopharma Inc Earnings

    Cue Biopharma Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci

Organization
Cue Biopharma Inc
Employees
51
CEO
Mr. Daniel R. Passeri J.D., M.Sc., MSc.
Industry
Health Technology

Discover More

FAQs